New York Ventures

We're thrilled to announce that New York Ventures, a program of Empire State Development, has placed their fourth investment in PostProcess Technologies! This injection of capital marks a significant milestone in PostProcess Technologies' Series C funding round. NY Ventures' decision to make an additional investment in PostProcess Technologies reflects its commitment to fostering technological innovation and driving economic growth within the state of New York. PostProcess Technologies plans to use the Series C funding to further enhance its product offerings, expand its market reach, and continue to build the infrastructure to rapidly scale the company. The additional investment from NY Ventures will play a pivotal role in propelling the company towards its strategic objectives and extending its position as the market leader in post-printing automation. To check out the full press release, visit our website! Jennifer Tegan, Jeff Mize, Hope Knight #additivemanufacturing #postprocessing #nyventures #pressrelease

We closed an oversubscribed $5.6M Seed Round! 🎉 🎉 🎉 We are thrilled to announce that we have closed a $5.6M Seed investment, co-led by Green Circle Foodtech Ventures and Fall Line Capital, with participation from Ponderosa Ventures, Golden Seeds and existing investor InMotion Ventures, the investment arm of JLR (Jaguar Land Rover). This incredible investment will leverage the work we’ve already achieved and catapult our mission to the next phase of success. We are beyond grateful for the support and belief in our work. Special thanks to Stu Strumwasser, Graham Anderson, Yanniv Dorone, Eric O'Brien, Evi Steyer, and Chloë Payne! #SustainableInnovation #LeatherAlternative  #SeedInvestment

Envisagenics has raised Series B financing to further develop novel therapeutics with our AI-driven drug discovery platform, SpliceCore®. Our platform integrates machine learning and high-performance computing to predict novel and disease-specific alternative splicing isoforms, utilizing one of the world’s largest databases of RNA splicing events. Envisagenics is now a revenue-generating and profitable company with a record 2023. A big thank you to our new and existing investors, including Bristol Myers Squibb, Third Kind Venture Capital, New York City Economic Development Corporation, and Red Cell Partners for partnering with us to unlock the therapeutic potential of RNA. Read the full press release to learn more. https://lnkd.in/eenaHwiE #Envisagenics #SeriesB #Biotech #DrugDiscovery #RNAsplicing #Innovation

The countdown is on! Only two weeks left to apply for our Year 10 program. This year, five companies will receive a $1 million investment in exchange for 5% equity, plus access to mentorship, connections, and more. But you can't be in it if you miss the deadline! Applications close on June 7th. APPLY: https://bit.ly/4bwm7Xh

Big news from PostProcess Technologies: We're thrilled to announce our 500th customer: Lucid Motors in California. Lucid Motors opted for our cutting-edge DEMI 4100, revolutionizing their resin removal workflow and boosting safety by ditching hazardous solvents like IPA. Since day one, we've been reshaping additive manufacturing post-processing with safety, efficiency, and innovation at the forefront. Now, with advanced algorithms and machine learning, we're empowering manufacturers to supercharge production cycles, enhance quality, and slash costs. Check out our website for the full press release! #postprocessing #additivemanufacturing #3dprinting

We are thrilled to share that we've been awarded the Top 100 Hispanic and Latino Venture Startups Award from Angeles Investors! At Envisagenics, we take immense pride in being a woman and minority-led startup that champions diversity in all aspects of our business. This recognition further fuels our unwavering dedication to fostering a diverse team. A huge thank you to Angeles Investors for acknowledging the incredible work our team continues to deliver. #AngelesInvestors #Envisagenics #DrugDiscovery